Serum Levels of proBNP in Patients with Acute Attack of Chronic Obstructive Pulmonary Disease with and without Heart Failure
Iranian Journal of Emergency Medicine,
Vol. 9 No. 1 (2022),
,
Page e21
https://doi.org/10.22037/ijem.v9i1.38585
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory disorders. Various studies have been conducted to evaluate the predictive power of proBNP (pro-brain natriuretic peptide) in heart diseases. The aim of this study was to compare the serum level of proBNP in patients with acute attack of chronic obstructive pulmonary disease with and without heart failure.
Methods: This cross-sectional study was conducted on 112 patients who presented to the Adalatian Emergency Department of Imam Reza Hospital of Mashhad University of Medical Sciences in 2016 and 2017. The serum level of proBNP was measured. Patients were subjected to echocardiography and Ejection Fraction evaluation by an experienced cardiologist using the image point HX echocardiography device. Finally, patients with and without heart failure were compared using SPSS version 16 software.
Results: 75 patients (66.96%) did not have heart failure and 37 patients (33.04%) had heart failure. Basic characteristics including age, gender, smoking, and drug abuse were not significantly different between the two groups. However, the average number of hospitalizations was 3.2 ± 1.6 in patients with heart failure and 1.7 ± 0.8 in those without heart failure (P=0.001). The average proBNP level in patients with heart failure (16702.1 ± 6660.0 pg/dL) was significantly higher than that of patients without heart failure (1396.8 ± 161.2 pg/dL) (P=0.001).
Conclusion: The level of proBNP is significantly higher in COPD patients with heart failure, and the number of hospitalizations is also significantly higher in these patients.
- Pulmonary disease
- chronic obstructive
- natriuretic peptide
- brain
- heart failure
How to Cite
References
Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798-807.
OM J. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2006;27(3):372.
van Gestel YR, Goei D, Hoeks SE, Sin DD, Flu W-J, Stam H, et al. Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2011;7(1):70-5.
Adrish M, Nannaka VB, Cano EJ, Bajantri B, Diaz-Fuentes G. Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction. International journal of chronic obstructive pulmonary disease. 2017;12:1183.
Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chronic respiratory disease. 2017;14(2):117-26.
Shaker H, Jafari Nodoushan M, Mashayekhian M, Hoseini Kasnavieh M, Basirghafouri H, Reyhani H. Assessment of Relationship between Serum Level of Aminoterminal pro B-type Natriuretic Peptide and Prognosis in Patients with Respiratory Distress. SSU_Journals. 2011;19(4):542-9.
Motamedi M, Saadat H, Namazi M, Safi M, Vakili H, Valaei N. Diagnostic Value of NT-BroBNP in HF Patients Admitted with Dyspnea in Emergency Department. Pajoohandeh Journal. 2010;14(5):241-5.
Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764-8.
Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195-203.
Christ M, Thuerlimann A, Laule K, Klima T, Hochholzer W, Perruchoud A, et al. Long‐term prognostic value of B‐type natriuretic peptide in cardiac and non‐cardiac causes of acute dyspnoea. European journal of clinical investigation. 2007;37(11):834-41.
Latini R, Masson S, Staszewsky L. Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. Expert Review of Cardiovascular Therapy. 2016;14(6):703-11.
Ghobadi H, Aslani MR, Hosseinian A, Farzaneh E. The correlation of serum brain natriuretic peptide and interleukin-6 with quality of life using the chronic obstructive pulmonary disease assessment test. Medical Principles and Practice. 2017;26(6):509-15.
- Abstract Viewed: 61 times
- pdf (فارسی) Downloaded: 36 times